New-born screening programs

Published by IRDiRC

Genetic Condition Newborn Sreening Programme Patient Information Rare Disease Research and Drug Development

The purpose of NBS is to detect potentially fatal or disabling conditions in newborns as early as possible and possibly before onset of symptoms. Such detection allows the early treatment which may significantly modify the natural history of the disease and potentially prevent developmental delays, physical disabilities and eventually death.

View this resource Bookmark this resource

Initiatives for undiagnosed diseases

Published by IRDiRC

Genetic Condition Genotype and Phenotype Matchmaking Patient Information Research and Drug Development Undiagnosed Disease Programme

The purposes of Undiagnosed Diseases Programs (UDPs) are to provide patients with an unknown genetic condition a diagnosis and to find the correlation between genotype and phenotype; to share globally the information to facilitate the diagnosis through a matchmaking for finding possible second cases

View this resource Bookmark this resource

FAIR principle for data use

Published by IRDiRC

FAIR Guideline Patient Registry Rare Disease Research and Drug Development

Lack of ultimate data use in rare disease created many silos slowing down development. The FAIR is coming to bridge this gap by proving essential guidelines for optimal data use.

View this resource Bookmark this resource

Feasibility-Patient engagement in trial endpoInternationalselection

Published by IRDiRC

Clinical Development Clinical Trial Endpoint Outcome Measure Patient Engagement Research and Drug Development Trail EndpoInternationalSelection

Guidance on the pivotal clinical trials outcomes measures .The important of the patient’s feedback. Academics can then assess whether there is an outcome measure available that can measure this – if not, outcome measure(s) may need to be developed.

View this resource Bookmark this resource

Feasibility-Patient engagement in trial design and feasibility

Published by IRDiRC

Eurordis Patient Engagement Patient Information Patient Organisation Patient Organisations Research and Drug Development

EURORDIS as first poInternationalof contact; the patient organization of the specific disease

View this resource Bookmark this resource

Registries for Rare Diseases

Published by IRDiRC

Database Patient Registry Registry for Rare Disease Research and Drug Development

Registries collect information on patients afflicted by a particular disease or group of diseases. By combining data on as many patients as possible, at the regional, national, European or global level, the potency of the data increases exponentially

View this resource Bookmark this resource

Natural History Studies (NHS)

Published by IRDiRC

Natural History Patient Data Research and Drug Development

A Natural History is the understanding of a disease progression throughout the lifespan of a patient. The collection of data from a significant number of patients affected by diverse phenotypes inside the same condition contribute to describe the history of a disease. It is a major issue in Rare Diseases research.

View this resource Bookmark this resource

Development of product specific bio-analytical assays

Published by IRDiRC

Bio-Analytical Assay Bioassay Drug Discovery Research and Drug Development

Measurement of drug concentrations in biological matrices (such as serum, plasma, blood, urine, and saliva) is an important aspect of drug development. These methods provide data to support the Safety and effectiveness of drugs, which may be needed to support applications for new drugs in regulatory pathways

View this resource Bookmark this resource

Technology Transfer Offices

Published by IRDiRC

Intellectual Property Project Management Technology Transfer Office

View this resource Bookmark this resource

Orphan Drug Development Guide

Published by IRDiRC

Database or Tool Orphan Drug Development Guide Research and Drug Development

These guidelines include tools, incentives, resources and practices for developing traditional and innovative drugs/therapies for rare diseases and how to best use them. It can be used by academic, non-profit organizations, small and larger (innovative) biotechs and patient-driven drug developers.

View this resource Bookmark this resource

The Innovation Management Toolbox was originally developed through funding from the EJP RD project, which received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 825575. The continued development and maintenance of the Toolbox are now supported by the ERDERA partnership, funded under the European Union’s Horizon Europe Research & Innovation programme, grant agreement No. 101156595.

IMT Feedback

Did the IMT help you in finding the resource you needed?